Karyopharm reports FY2023 total rev $146M, XPOVIO net $112M; guides 2024 total $140-160M

Karyopharm Therapeutics Inc.

2023-FY EPS reported -$1.25 revenue$146,033,000

Full year 2023 total revenue $146.0M (down from $157.1M YoY); net loss $143.1M ($1.25/sh) vs $165.3M loss in 2022.
Q4 2023 XPOVIO net product revenue $25.1M; full year $112.0M, down ~7% YoY due to competition and PAP utilization.
Three pivotal Phase 3 top-line readouts expected in 2025: endometrial cancer, myelofibrosis, multiple myeloma.
2024 guidance: total revenue $140-160M, XPOVIO net $100-120M, R&D+SG&A $260-280M, cash runway to late 2025.
Cash, equivalents and investments $192.4M as of Dec 31, 2023 vs $279.7M a year earlier.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Karyopharm Therapeutics Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue Total Revenue of $146 Million. Guidance reaffirmed.

Period: the fourth quarter and full year ended December 31, 2023
Revenue: Total Revenue of $146 Million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress – Total Revenue of $146 Million and U.S. XPOVIO ® (selinexor) Net Product Revenue of $112 Million for Full Year 2023, Meeting Company’s Guidance

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-051845

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.